Patent · US Active

Antibodies that target HIV GP120 and methods of use

US11987617B2 · kind B2 · utility

1Cited by

24References

21Claims

0Family size

Assignee

Gilead Sciences, Inc. · US

Inventors

Mini Balakrishnan · San Mateo, US
Brian Carr · Raleigh, US
Magdeleine S. Hung · Mountain View, US
Manu Kanwar · San Marcos, US
Doug Rehder · Bonsall, US
Matthew R. Schenauer · Dana Point, US
Loredana Serafini · Orinda, US
Nathan D. Thomsen · Castro Valley, US

Key dates

Filing date	Aug 4, 2023
Grant date	May 21, 2024
Priority date	—
Expiry date	Aug 4, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Antibodies that bind to HIV gp120 and neutralize HIV are disclosed. Also disclosed are methods of using such antibodies alone or in combination with other therapeutic agents to treat or prevent HIV infection.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.